fe2380ce17
- Source: inbox/queue/2026-04-23-icer-glp1-affordable-access-2025.md - Domain: health - Claims: 1, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
13 lines
No EOL
1.2 KiB
Markdown
13 lines
No EOL
1.2 KiB
Markdown
# Institute for Clinical and Economic Review (ICER)
|
|
|
|
## Overview
|
|
ICER is the most rigorous independent health technology assessment organization in the United States, conducting evidence-based evaluations of medical interventions and their cost-effectiveness.
|
|
|
|
## Timeline
|
|
- **2025-04-09** — Published white paper "Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions" in collaboration with Brown University, synthesizing literature and stakeholder interviews (PBMs, manufacturers, patient advocacy groups, benefit consultants, state/Medicaid experts)
|
|
|
|
## Significance
|
|
ICER's April 2025 GLP-1 white paper was criticized by the National Pharmaceutical Council for "prioritizing payers over patients," reflecting the structural tension between cost-effectiveness analysis and access equity. The white paper focuses on payer sustainability strategies rather than access expansion, documenting that self-insured employers saw >10x PMPM cost increases from January 2023 to December 2024.
|
|
|
|
## Related Work
|
|
A peer-reviewed version of the white paper was published as "Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US" (PMC12403326). |